CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of Company’s US$6.0 million 10% secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink"), and payment of accrued interest thereon, extending the maturity date to May 13, 2023.
“We are extremely pleased that our partner Hepalink has extended the debenture’s maturity date. This speaks volumes to the ongoing supportive and collaborative partnership we have with Hepalink, and our common goal of bringing lifesaving therapies to highly unmet medical needs,” stated Donald McCaffrey, President & CEO of Resverlogix.
Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression by regulating the expression of disease-causing genes.
Due to the extensive role for BET proteins in the human body, apabetalone, can simultaneously target multiple disease-related biological processes while maintaining a well-described safety profile – leading to a new way to treat chronic disease. Apabetalone received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) and is the only drug of its class with an established safety record in human clinical trials, with well over 4200 patient-years on drug across 10 clinical trials.
Following a publication in Nature, authored by a consortium of top Universities and Research Institutions, on March 23, 2020, Resverlogix launched a COVID-19 program, conducting research internally and enlisting world-renowned collaborators. Studies – published in prestigious scientific journals (including Cell) – demonstrate that apabetalone has the potential to act against COVID-19 with a unique dual-mechanism: first by preventing viruses from entering the cells and replicating; and second by averting excessive inflammatory reactions that can cause severe and lasting organ damage.
A Phase 2b clinical trial is evaluating apabetalone in combination with standard of care for patients hospitalized with COVID-19. The investigational treatment could potentially reduce the severity and duration of COVID-19. Apabetalone’s unique dual-mechanism also means that it has the potential to show efficacy against new COVID-19 variants and may even help fight other viruses.
Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for COVID-19 in Canada and the United States. EVERSANA™ is currently leading clinical outreach and advocacy for apabetalone in the Canadian market.
In February 2020, apabetalone became the first therapy of its kind to receive Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) – for a major cardiovascular indication – following the ground-breaking findings from the BETonMACE Phase 3 study. Data from BETonMACE showed apabetalone can potentially prevent major adverse cardiac events among high-risk cardiovascular disease patients who also have type 2 diabetes mellitus.
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics, or gene regulation, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.
Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
The Company’s clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and COVID-19.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us: Twitter: @Resverlogix_RVX. LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
Forward Looking Statements:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information related to the Company’s Phase 2b COVID-19 clinical trial and the potential treatment of COVID-19 patients with apabetalone (and potentially other viruses), as well as cardiovascular disease and associated comorbidities and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please contact: